Mechanisms underlying the biological changes induced by isocitrate dehydrogenase‑1 mutation in glioma cells

Wang,Ju‑Bo; Dong,Dan‑Feng; Gao,Ke; Wang,Mao‑De

doi:10.3892/ol.2014.1806

Mechanisms underlying the biological changes induced by isocitrate dehydrogenase‑1 mutation in glioma cells

Authors:
- Ju‑Bo Wang
- Dan‑Feng Dong
- Ke Gao
- Mao‑De Wang
View Affiliations

Affiliations: Department of Neurosurgery, First Affiliated Hospital of the Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Oncology, First Affiliated Hospital of the Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: January 16, 2014 https://doi.org/10.3892/ol.2014.1806
Pages: 651-657

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Isocitrate dehydrogenase 1 (IDH1) mutation has been reported to be associated with an increased overall survival in patients with glioma in a number of studies. Previous studies have focused on the mutation rate and possible metabolic pathways of the mutated IDH1 gene. However, the effects of IDH1 mutation on the biological behavior of glioma cells and the associated mechanisms, as well as the possible effects they may have on clinical therapy, have not been studied. In the present study, three eukaryotic expression vectors were constructed and transfected into the U87 cell line, specifically, a wild‑type form of the IDH1 gene with the enhanced green fluorescent protein (EGFP) gene, a mutated IDH1 gene with the EGFP gene and the EGFP gene only. The three stable cell lines were selected using the G418 antibiotic. The biological behaviors of the cell lines were studied and the mechanisms underlying the biological differences between the cell lines were further investigated. The present study confirmed that IDH1 mutation induced cell cycle arrest in the G1 phase and reduced the proportion of the G2/M phase, by downregulating cell division control protein 2 homolog levels, increasing bromodomain‑containing protein 2 levels and markedly limiting cell proliferation. IDH1 mutation had no effect on the apoptosis rate under routine culture conditions. Serum chemotaxis assays showed that IDH1 mutation was markedly associated with a significantly reduced invasion ability, by reducing the levels of matrix metalloproteinase (MMP)‑2 and MMP‑9. From this study, it may be concluded that IDH1 mutation improves prognosis in glioma patients by altering the cell cycle, inhibiting cell proliferation and downregulating cell invasion ability. The results may provide a partial explanation for the improved prognosis of patients with mutated forms of the IDH1 gene.

View Figures

View References

1	Wakabayashi T: Clinical trial updates for malignant brain tumors. Rinsho Shinkeigaku. 51:853–856. 2011.(In Japanese).
2	Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 15(Suppl 2): 1–56. 2013.PubMed/NCBI
3	Ohgaki H: Epidemiology of brain tumors. Methods Mol Biol. 472:323–342. 2009. View Article : Google Scholar : PubMed/NCBI
4	Combs SE, Gutwein S, Schulz-Ertner D, van Kampen M, Thilmann C, Edler L, et al: Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol. 181:372–377. 2005. View Article : Google Scholar
5	Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
6	Onishi M, Ichikawa T, Kurozumi K and Date I: Angiogenesis and invasion in glioma. Brain Tumor Pathol. 28:13–24. 2011. View Article : Google Scholar : PubMed/NCBI
7	Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al: An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
8	Hathaway JA and Atkinson DE: The effect of adenylic acid on yeast nicotinamide adenine dinucleotide isocitrate dehydrogenase, a possible control mechanism. J Biol Chem. 238:2875–2881. 1963.
9	Barnes LD, McGuire JJ and Atkinson DE: Yeast diphosphopyridine nucleotide specific isocitrate dehydrogenase. Regulation of activity and unidirectional catalysis. Biochemistry. 11:4322–4329. 1972. View Article : Google Scholar
10	Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI
11	Geer BW, Kamiak SN, Kidd KR, Nishimura RA and Yemm SJ: Regulation of the oxidative NADP-enzyme tissue levels in Drosophila melanogaster. I. Modulation by dietary carbohydrate and lipid. J Exp Zool. 195:15–32. 1976. View Article : Google Scholar
12	Wilton AN, Laurie-Ahlberg CC, Emigh TH and Curtsinger JW: Naturally occurring enzyme activity variation in Drosophila melanogaster. II. Relationships among enzymes. Genetics. 102:207–221. 1982.PubMed/NCBI
13	Aghili M, Zahedi F and Rafiee E: Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J Neurooncol. 91:233–236. 2009. View Article : Google Scholar : PubMed/NCBI
14	Capper D, Simon M, Langhans CD, Okun JG, Tonn JC, Weller M, von Deimling A and Hartmann C; German Glioma Network. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer. 131:766–768. 2012. View Article : Google Scholar
15	Nobusawa S, Watanabe T, Kleihues P and Ohgaki H: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 15:6002–6007. 2009. View Article : Google Scholar : PubMed/NCBI
16	Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
17	Zhu J, Zuo J, Xu Q, Wang X, Wang Z and Zhou D: Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. Med Hypotheses. 76:602–603. 2011. View Article : Google Scholar
18	Chen YN, Chen JC, Yin SC, Wang GS, Tsauer W and Hsu SL: Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer. 100:158–165. 2002. View Article : Google Scholar : PubMed/NCBI
19	Kim DI, Lee SJ, Lee SB, Park K, Kim WJ and Moon SK: Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression. Carcinogenesis. 29:1701–1709. 2008. View Article : Google Scholar : PubMed/NCBI
20	Qiao F, Zuo D, Shen X, Qi H, Wang H, Zhang W and Wu Y: DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080. Cancer Chemoth Pharmacol. 70:259–270. 2012. View Article : Google Scholar : PubMed/NCBI
21	Hogan FS, Krishnegowda NK, Mikhailova M and Kahlenberg MS: Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res. 143:58–65. 2007. View Article : Google Scholar : PubMed/NCBI
22	Denis GV, Vaziri C, Guo N and Faller DV: RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. Cell Growth Differ. 11:417–424. 2000.
23	Ottinger M, Pliquet D, Christalla T, Frank R, Stewart JP and Schulz TF: The interaction of the gammaherpesvirus 68 orf73 protein with cellular BET proteins affects the activation of cell cycle promoters. J Virol. 83:4423–4434. 2009. View Article : Google Scholar : PubMed/NCBI
24	Wang F, Liu H, Blanton WP, Belkina A, Lebrasseur NK and Denis GV: Brd2 disruption in mice causes severe obesity without type 2 diabetes. Biochem J. 425:71–83. 2009. View Article : Google Scholar : PubMed/NCBI
25	Shang E, Wang X, Wen D, Greenberg DA and Wolgemuth DJ: Double bromodomain-containing gene Brd2 is essential for embryonic development in mouse. Dev Dyn. 238:908–917. 2009. View Article : Google Scholar : PubMed/NCBI
26	Woolston CM, Zhang L, Storr SJ, Al-Attar A, Shehata M, Ellis IO, Chan SY and Martin SG: The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer. Modern Pathol. 25:1106–1116. 2012. View Article : Google Scholar
27	Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P, Sastre-Garau X and Mechta-Grigoriou F: miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nature Med. 17:1627–1635. 2011. View Article : Google Scholar : PubMed/NCBI